You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
A new study of a β-thalassemia gene therapy appears promising, according to NPR.
The Telegraph reports that UK regulators gave CRISPR Therapeutics the go-ahead for its beta thalassemia clinical trial.
The researchers plan to use ArcherDX's technology to evaluate minimal residual disease in pediatric AML patients participating in a clinical trial.
Technology Review writes that though CRISPR trials in people are beginning, studies in monkeys haven't provided much data.
"Repurposing starts with the human genome," a precision medicine expert said in explaining Vanderbilt's new approach to accelerating clinical trials.
Some cancer researchers are pushing to relax clinical trial eligibility requirements, according to Nature.
The company now partners with 10 healthcare systems to provide free NGS testing to all advanced cancer patients and plans to present patient data this summer.
With its technology, the company hopes to connect more cancer patients being treated in community-based practices to beneficial clinical trials based on genomic biomarkers.
The firm's Guardant360 assay will be used first to test patients for ERBB2 mutations, then guide patients to a variety of treatment arms.
The Financial Times reports that CRISPR-based biotechs are about to start human studies of gene-editing treatments.
A study of families explores how children transmit SARS-CoV-2, according to the Associated Press.
US Agricultural Research Service scientists have sequenced the genome of the Asian giant hornet.
According to the Economist, pooled testing for COVID-19 could help alleviate strains on testing labs.
In Science this week: MIT researchers outline approach dubbed translatable components regression to predict treatment response among IBD patients.